Dr Anoop Enjeti

Anoop Enjeti
Research Program:
Research Topics:
Project Grant
2018 Project Grant
Project Grant
2018 Project Grant
Project Grant
2018 Project Grant
Project Grant
2017 Project Grant
Project Grant
2017 Project Grant
Project Grant
2010 Project Grant

What are your research interests?

  • Haematology ( study of blood disorders)
  • Transfusion
  • Leukemia (blood cancers)
  • Coagulation (clotting) and venous thromboembolism

Why did you get into research?

Blood cancers are devasting for the patient and their families. As a clinician researcher, the unique opportunity to work with patients and to translate the developments in the lab directly to clinical practice is a constant inspiration in the journey to treat blood diseases.

What would be the ultimate goal for your research?

Working with my clinical colleagues, students and other researchers, we aim to bring novel drugs and diagnostics as well as introduce health system changes, bring world class research in haematology to the Hunter to improve outcomes for patients with blood disorders.

Biography

Dr Enjeti obtained his postgraduate physician qualifications from the UK Royal College of Physicians and specialist haematology from the Royal College of Pathologists of Australasia (2006). His physician and specialist haematology training has spanned across India, UK, Singapore and Australia including specialist training in genetics and molecular genetics where he has contributed to a high impact publication outlining geographical variations in AML genetics. Other training includes a MD in Pathology (Pondicherry University 2001), GradCert in Bioethics (Monash, 2012) as well as Masters in Clinical Epidemiology (Molecular Genetics, University of Newcastle 2010).

Dr Enjeti is currently employed as a clinical haematologist at the Calvary Mater Hospital, with a special interest in acute myeloid leukaemia (blood cancer) and myelodysplasia (precursor to blood cancer). He is an active member of the Hunter Cancer Research Alliance (HCRA) where he has established active collaborations with cancer researchers locally and across the state.  He has over 35 peer-reviewed publications, numerous conference presentations and three book chapters.

Dr Enjeti is the recipient of the prestigious ‘visiting fellowship’ in Molecular Oncologic Pathology Strategic Health Research Training Program in Cancer Research, Canada (funded by the Terry Fox Foundation) for the year 2016. Dr Enjeti was the recipient of the HCRA fellowship in 2015 and more recently was awarded aTranslational Research Fellowship from Pathology NSW - Hunter/HNE LHD /HCRA and Calvary Mater Hospital (2017-19) to pursue translational clinical research in Haematology. His research focus includes early phase clinical trials in haematological malignancies( AML/MDS) and translational diagnostics as well as in circulating microvesicles and their impact on thrombosis/cancer/abnormal clonal haemopoiesis (his PhD work).

Dr Enjeit manages several current acute leukemia, myeloma and myelodysplasia clinical trials (has been an investigator in > 25 past clinical trials) at the Calvary Mater Hospital. He is an active member of ALLG (Australasian Leukemia and Lymphoma Group) subcommittees - leukemia disease group and the basic science subcommittees. He is currently a principal investigator at his site for several ongoing national and international trials in Myeloma, lymphoma, leukemia and myelodysplasia. He has strong research interest in exploring novel oral therapies for haematological malignancies and an international phase I trial , in which he was a principal investigator led to FDA  approval of a new therapy for blood cancer .He also is the molecular haematology lead for his hospital and has been instrumental in setting up array as well as next generation sequencing for molecular targeting / prognostication in Myeloma, lymphoid and other myeloid malignancies at Pathology North/ Pathology NSW.

Future Focus

Both laboratory and clinical research in Haematology

Specialised/Technical Skills

  • Early phase clinical trials with focus on MDS and AML
  • Translational diagnostics in Haemtatology
  • Service  transformation projects with focus on transfusion
  • Understanding the biology of coagulation and  risk reduction  strategies for venous thromboembolism

Affiliations

2018

Predicting tOxicity for Myeloma Therapy (PrOMT)
Project Grant
Researchers:
Description:

Multiple myeloma (MM) is a cancer of plasma cells, which are mature white blood cells within the bone marrow. The disease causes bone pain, fractures, infections, anaemia and renal failure. It typically affects people over the age of 60, with about 1700 new diagnoses each year in Australia.[1] It is incurable and carries a life expectancy of 2-7 years depending on the aggressiveness of the tumour cells.

more
Haematology Research
Project Grant
Researchers:

Dr Anoop Enjeti, Ms Nadine Berry

Teaching old dogs new tricks – PARP inhibitors as treatments for childhood cancers
Project Grant
Description:

Cancer is the most common cause of childhood disease-related deaths, with leukaemia the most common childhood cancer in Australia.

more

2017

Genome wide approach to risk assess Multiple Myeloma and precursor plasma cell disorders
Project Grant
Researchers:

Dr Anoop Enjeti, Ms Nadine Berry, Dr Wojt Janowski, L/Prof Rodney Scott, Prof Philip Rowlings

Description:

Multiple myeloma (MM) is a cancer of plasma cells, which are mature white blood cells within the bone marrow. The disease causes bone pain and weakening which often leads to fractures. It typically affects people over the age of 60, with about 1700 new diagnoses each year in Australia. It is incurable and carries a life expectancy of 2-7 years depending on the aggressiveness of the tumour cells. Although the actual cause of MM is unknown, it is often preceded by less severe forms of the disease called monoclonal gammopathy of undetermined significance (MGUS), and smouldering multiple myeloma (SMM). However, not everyone with these early stages will develop MM, and it is not clear what drives progression of the disease. 

more
Re-purposing PARP inhibitors to treat childhood leukaemias
Project Grant
Description:

Cancer is the most common cause of childhood disease-related deaths, with leukaemia the most common childhood cancer in Australia. The two most common forms of leukaemia in children are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Whilst remission is achievable in over 95% of ALL cases, 1/3 of patients will relapse within 5 to 10 years, and these children will not be long-term survivors. AML accounts for 20% of all childhood leukaemias, and the outlook for children diagnosed with AML is much worse, with only approximately half of children surviving for 5 years post-diagnosis.

more

2010

Targeting PP2A as a novel therapeutic Strategy for mutant FLT3+ Acute Myeloid Leukaemia
Project Grant
Researchers: